The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
MOMGEMFIN: Real-world study of momelotinib in patients with MF and anemia
Momelotinib is approved by the U.S. FDA and EMA for treatment of splenomegaly and disease-related symptoms in adult patients with MF and anemia. However, real-world data on momelotinib use in routine clinical practice are limited. Results from MOMGEMFIN, a real-world retrospective analysis evaluating the efficacy and safety of momelotinib in patients with MF and anemia, were published by Pérez-Lamas et al. in Blood Cancer Journal.1 The GEMFIN-initiated multicenter, retrospective analysis included 122 patients with primary or secondary MF and anemia, assessed using the 2024 IWG-ELN criteria, who were either JAKi-naive or -exposed and were treated with momelotinib. Patients were grouped according to transfusion-dependent anemia (TDA; n = 90) and non-TDA (n = 32).
|
Key learnings1 |
At 3 months, 26.9% and 47.8% of patients achieved a major response with momelotinib in the TDA and non-TDA groups, while 30.6% and 36.4% achieved a major response at 6 months, respectively. |
ORRs were 50% vs 60% at 3 months and 62.5% vs 67.8% at 6 months in JAKi-naive vs JAKi-exposed TDA patients. In non-TDA patients, ORRs were 16.6% vs 70.6% at 3 months and 25.0% vs 85.7% at 6 months in JAKi-naive vs JAKi-exposed patients, respectively. |
Among patients in the TDA group, 48.4% and 45.7% achieved transfusion independence at 3 and 6 months, respectively, with momelotinib. |
Momelotinib was safe and well-tolerated. The most common hematological AE was thrombocytopenia (10.3%), and non-hematological AEs were diarrhea (11.7%) and infection (9%). |
The findings are consistent with the MOMENTUM and SIMPLIFY-2 trials, providing valuable real-world evidence to support the use of momelotinib in clinical practice for patients with MF and anemia who are either JAKi-naive or JAKi-exposed. |
Abbreviations: AE, adverse event; EMA, European Medicines Agency; FDA, U. S. Food and Drug Administration; GEMFIN, Spanish Group of Philadelphia-negative Myeloproliferative Neoplasms; IWG-ELN, International Working Group-European LeukemiaNet; JAKi, Janus kinase inhibitor; MF, myelofibrosis; ORR, overall response rate; TDA, transfusion-dependent anemia.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?
